A Service For Professionals Friday, November 17, 2017
Contact (202) 540-8337
Company News Today
A Service For Professionals Friday, November 17, 2017 11614 Sources 416,239,250 Articles 3,022,490 Readers
Contact (202) 540-8337

Global Transdermal Patch Market & Clinical Pipeline Outlook 2022

/EIN News/ -- Dublin, May 12, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Transdermal Patch Market & Clinical Pipeline Outlook 2022" report to their offering.

Global Transdermal Patch Market & Clinical Pipeline Outlook 2022 report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies. Currently there 40 transdermal patches available in the market and more than 70 patches are in clinical pipeline.

Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch.

Strong clinical pipeline could be observed in case of transdermal patches which reflect the interest of pharmaceutical companies in this segment. Before marketing approval they have to undergo strict testing and checking for various qualitative parameters. They must be stable, chemically unreactive, hypo allergic, nontoxic and easy to manufacture. High throughput methods are expected to increase the suitable polymer screening rates along with reduced time consumption. Bioequivalence of therapeutic in transdermal patch with same drug administrated via different route have known efficacy must be shown. Similarly, independent of patch type they must show bioequivalence in clinical trials before getting marketing approval from medical regulatory authorities. Various products are at different stages of clinical trials which will be introduced in global market in coming years.

Global Transdermal Patch Market & Clinical Pipeline Outlook 2022 report highlights:

- Introduction & Classification of Transdermal Patch
- Mechanism of Transdermal Patch Drug Delivery
- Transdermal Patch v/s Traditional Drug Delivery Methods
- Global Transdermal Patch Clinical Pipeline Overview
- Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase
- Global Transdermal Patch Market Future Prospects

Key Topics Covered:

1. Introduction to Transdermal Patch

2. Classification of Transdermal Patches
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch

3. Why There Exist Need for Transdermal Patches?

4. Mechanism of Transdermal Patch Drug Delivery
4.1 Properties of Transdermal Therapeutics
4.2 Components of Transdermal Patch
4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch

5. Transdermal Patch v/s Traditional Drug Delivery Methods

6. Global Transdermal Patch Market Outlook
6.1 Global Market Scenario
6.2 Regional Trends

7. Global Transdermal Patch Clinical Pipeline Overview
7.1 By Phase
7.2 By Region/Country
7.3 By Drug Class/Molecule
7.4 By Company
7.5 By Orphan & Fast Track Status
7.6 By Mode of Action

8. Global Transdermal Patch Market Dynamics
8.1 Favorable Market Parameters
8.2 Commercialization Challenges

9. Global Transdermal Patch Market Future Prospects

10. Global Transdermal Patch Clinical Insight
10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-II/III
10.9 Phase-III
10.10 Preregistration
10.11 Registered

11. Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase

12. Competitive Landscape
12.1 3M Pharmaceuticals
12.2 Acrux
12.3 Agile Therapeutics
12.4 Allergan
12.5 ANI Pharmaceuticals
12.6 Antares Pharma
12.7 Bayer HealthCare Pharmaceuticals
12.8 Corium International
12.9 Chase Pharmaceuticals
12.10 DURECT Corporation
12.11 Endo Pharmaceuticals
12.12 Fempharm
12.13 Hisamitsu Pharmaceutical
12.14 Immune Pharmaceuticals
12.15 Imprimis Pharmaceuticals
12.16 Ipsen Bioscience
12.17 Johnson & Johnson
12.18 LaSalle Laboratories
12.19 Lavipharm-increase
12.20 MINRAD International
12.21 NeurogesX
12.22 Noven Pharmaceuticals
12.23 NuPathe
12.24 Nuvo Research
12.25 Novartis
12.26 Pain Therapeutics
12.27 ProStrakan
12.28 Purdue Pharma
12.29 Sanofi
12.30 Scilex Pharmaceuticals
12.31 Senju Pharmaceutical
12.32 Somerset Pharmaceuticals
12.33 Teikoku Seiyaku
12.34 Therapeutic Discovery Corporation
12.35 Transdermal Delivery Solutions Corp
12.36 UCB-full form
12.37 Xel Pharmaceuticals
12.38 Zosano Pharma

For more information about this report visit http://www.researchandmarkets.com/research/d2p9zx/global


                    
                    
                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             U.S. Fax: 646-607-1907
                             Fax (outside U.S.): +353-1-481-1716
                             Related Topics: Transdermal and Transmucosal Drug Delivery
                    

Primary Logo

Powered by EIN News